X4 Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
XFOR$3.33+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. FINANCIAL STATEMENTS
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(unaudited)
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $97,412 | $99,216 |
| Marketable securities | 37,565 | 15,000 |
| Research and development incentive receivable | 1,073 | 562 |
| Inventory | 2,445 | — |
| Prepaid expenses and other current assets | 4,477 | 7,298 |
| Total current assets | 142,972 | 122,076 |
| Property and equipment, net | 820 | 745 |
| Goodwill | 17,351 | 17,351 |
| Intangible asset, net | 10,188 | — |
| Right-of-use assets | 4,471 | 5,650 |
| Other assets | 2,363 | 1,436 |
| Total assets | $178,165 | $147,258 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,577 | $8,947 |
| Accrued expenses (Note 9) | 19,459 | 12,816 |
| Current portion of lease liability | 1,222 | 1,099 |
| Total current liabilities | 29,258 | 22,862 |
| Long-term debt, including accretion, net of discount | 75,224 | 54,570 |
| Lease liabilities | 1,757 | 2,612 |
| Warrant liability (Note 5) | 11,087 | 15,683 |
| Other liabilities | 1,218 | 432 |
| Total liabilities | 118,544 | 96,159 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value, 500,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 168,511,264 and 167,434,595 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 168 | 167 |
| Additional paid-in capital | 535,101 | 528,956 |
| Accumulated other comprehensive loss | (114) | (119) |
| Accumulated deficit | (475,534) | (477,905) |
| Total stockholders’ equity | 59,621 | 51,099 |
| Total liabilities and stockholders’ equity | $178,165 | $147,258 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.